Establishment Labs Holdings Inc. (ESTA) – What Are Brokerages Thinking About This Stock?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $98.56.

ESTA has been the subject of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. TD Cowen reaffirmed a “buy” rating and issued a $117.00 target price on shares of Establishment Labs in a research note on Thursday, October 15th. Canaccord Genuity Group set a $105.00 target price on shares of Establishment Labs in a research note on Thursday, August 6th. Stifel Nicolaus set a $85.00 target price on shares of Establishment Labs and gave the company a “buy” rating in a research report on Wednesday, October 14th. Finally, Mizuho boosted their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th.

Establishment Labs Trading Up 4.8%

Shares of NASDAQ ESTA opened at $61.07 on Friday. Establishment Labs has a 52 week low of $47.00 and a 52 week high of $97.59. The business has a 50-day simple moving average of $68.69 and a two-hundred day simple moving average of $74.53. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. Establishment Labs’s revenue was up 31.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.57) EPS. On average, equities analysts predict that Establishment Labs will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

A number of large investors have recently added to or reduced their stakes in ESTA. BlackRock Inc. purchased a new stake in shares of Establishment Labs during the second quarter valued at approximately $135,752,000. William Blair Investment Management LLC bought a new stake in shares of Establishment Labs during the second quarter valued at approximately $61,273,000. Bank of America Corp DE bought a new stake in shares of Establishment Labs during the second quarter valued at approximately $52,176,000. Rice Hall James & Associates LLC purchased a new position in Establishment Labs in the 2nd quarter worth approximately $48,134,000. Finally, Nantahala Capital Management LLC purchased a new position in Establishment Labs in the 2nd quarter worth approximately $28,817,572. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.